nach oben

Hepatology International

Erschienen in:

01.12.2009 | Original Article

Outcomes of patients with chest tube insertion for hepatic hydrothorax

verfasst von: Eric S. Orman, Anna S. F. Lok

Erschienen in: Hepatology International | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Case reports and small case series have reported a high rate of complications associated with chest tube placement for hepatic hydrothorax. We describe the in-hospital and 3-month outcomes of patients who have had this procedure.

Methods

A retrospective medical record review was performed of all patients admitted to a tertiary care center over a 10-year period with a chest tube placed for hepatic hydrothorax. Demographic data and outcomes were collected and analyzed.

Results

Seventeen patients were identified; 12 were taking diuretics and 8 were taking multiple diuretics at the time of admission. MELD score was 14 (range = 7–34). During hospitalization, 16 had at least 1 and 12 had more than 1 complications. The most common complications were acute kidney injury (n = 11), pneumothorax (n = 7), and empyema (n = 5). Two patients died during the index admission and four others within 3 months of that admission. Six of seven patients who received TIPS survived.

Conclusions

Chest tube insertion for hepatic hydrothorax carries significant morbidity and mortality, with questionable benefit.

Cardenas A, Kelleher T, Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004;20:271–279CrossRefPubMed

Milanez de Campos JR, Andrade Filho LO, de Campos Werebe E, et al. Hepatic hydrothorax. Semin Respir Crit Care Med 2001;22:665–674CrossRefPubMed

Kinasewitz GT, Keddissi JI. Hepatic hydrothorax. Curr Opin Pulm Med 2003;9:261–265CrossRefPubMed

Lazaridis KN, Frank JW, Krowka MJ, Kamath PS. Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med 1999;107:262–267CrossRefPubMed

Xiol X, Tremosa G, Castellote J, Gornals J, Lama C, Lopez C, et al. Liver transplantation in patients with hepatic hydrothorax. Transpl Int 2005;18:672–675CrossRefPubMed

Feldman M, Friedman LS, Brandt LJ. Sleisenger & Fordtran’s gastrointestinal and liver disease. 8th ed. Philadelphia: W.B. Saunders; 2006

Liu LU, Haddadin HA, Bodian CA, Sigal SH, Korman JD, Bodenheimer HC Jr, et al. Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest 2004;126:142–148CrossRefPubMed

Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum HE, Rossle M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001;13:529–534CrossRefPubMed

Jeffries MA, Kazanjian S, Wilson M, Punch J, Fontana RJ. Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transpl 1998;4:416–423CrossRef

10.

Cerfolio RJ, Bryant AS. Efficacy of video-assisted thoracoscopic surgery with talc pleurodesis for porous diaphragm syndrome in patients with refractory hepatic hydrothorax. Ann Thorac Surg 2006;82:457–459CrossRefPubMed

11.

Ferrante D, Arguedas MR, Cerfolio RJ, Collins BG, van Leeuwen DJ. Video-assisted thoracoscopic surgery with talc pleurodesis in the management of symptomatic hepatic hydrothorax. Am J Gastroenterol 2002;97:3172–3175CrossRefPubMed

12.

Milanez de Campos JR, Filho LO, de Campos Werebe E, Setter H Jr, Fernandez A, Filomeno LT, et al. Thoracoscopy and talc poudrage in the management of hepatic hydrothorax. Chest 2000;118:13–17CrossRefPubMed

13.

Borchardt J, Smirnov A, Metchnik L, Malnick S. Lesson of the week: treating hepatic hydrothorax. BMJ 2003;326:751–2CrossRefPubMed

14.

Runyon BA, Greenblatt M, Ming RH. Hepatic hydrothorax is a relative contraindication to chest tube insertion. Am J Gastroenterol 1986;81:566–567PubMed

15.

Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc 2006;3:75–80CrossRefPubMed

16.

Ibrisim D, Cakaloglu Y, Akyuz F, Karadag A, Ozdil S, Besisik F, et al. Treatment of hepatic hydrothorax with terlipressin in a cirrhotic patient. Scand J Gastroenterol 2006;41:862–865CrossRefPubMed

17.

Pfammatter R, Quattropani C, Reichen J, Goke B, Wagner AC. Treatment of hepatic hydrothorax and reduction of chest tube output with octreotide. Eur J Gastroenterol Hepatol 2001;13:977–980CrossRefPubMed

18.

Chen A, Ho YS, Tu YC, Tang HS, Cheng TC. Diaphragmatic defect as a cause of massive hydrothorax in cirrhosis of liver. J Clin Gastroenterol 1988;10:663–666PubMedCrossRef

19.

Wong F. Hepatorenal syndrome: current management. Curr Gastroenterol Rep 2008;10:22–29CrossRefPubMed

20.

Karwa R, Woodis CB. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother 2009;43:692–699CrossRefPubMed

21.

Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the Consensus Conference of the International Ascites Club. Hepatology 2003;38:258–266CrossRefPubMed

22.

Wilputte JY, Goffette P, Zech F, Godoy-Gepert A, Geubel A. The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients. Acta Gastroenterol Belg 2007;70:6–10PubMed

23.

Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. J Vasc Interv Radiol 2002;13:385–390CrossRefPubMed

24.

Gordon FD, Anastopoulos HT, Crenshaw W, Gilchrist B, McEniff N, Falchuk KR, et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997;25:1366–1369CrossRefPubMed

25.

Andrade RJ, Martin-Palanca A, Fraile JM, Alcantara R, Carmona C, Medina MC, et al. Transjugular intrahepatic portosystemic shunt for the management of hepatic hydrothorax in the absence of ascites. J Clin Gastroenterol 1996;22:305–307CrossRefPubMed

26.

Conklin LD, Estrera AL, Weiner MA, Reardon PR, Reardon MJ. Transjugular intrahepatic portosystemic shunt for recurrent hepatic hydrothorax. Ann Thorac Surg 2000;69:609–611CrossRefPubMed

27.

Dumortier J, Lepretre J, Scalone O, Boillot O, Scoazec JY, Delafosse B, et al. Successful treatment of hepatic hydrothorax with octreotide. Eur J Gastroenterol Hepatol 2000;12:817–820CrossRefPubMed

28.

Haskal ZJ, Zuckerman J. Resolution of hepatic hydrothorax after transjugular intrahepatic portosystemic shunt (TIPS) placement. Chest 1994;106:1293–1295CrossRefPubMed

Titel: Outcomes of patients with chest tube insertion for hepatic hydrothorax
verfasst von: Eric S. Orman
Anna S. F. Lok
Publikationsdatum: 01.12.2009
Verlag: Springer-Verlag
Erschienen in: Hepatology International / Ausgabe 4/2009
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-009-9136-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C

Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation

Combined hepatocellular and cholangiocarcinoma with sarcomatoid transformation: radiologic–pathologic correlation of a case

Serum α-fetoprotein levels in liver steatosis

Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis

Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas